Q1 Interim report July - September 2023
ABOUT HAMLET BIOPHARMA Hamlet BioPharma is developing innovative drugs for the treatment of cancer and infections. The drug candi- dates aim to address unmet medical needs in large patient groups. Based on highly innovative scientific discoveries, the company is leveraging extensive IP for these innovative drugs. Hamlet BioPharma is progressing through the clinical development with three projects in Phase II trials. Bladder cancer treatment. The investigational new drug Alpha1H is in Phase II clinical trials, for the treatment of early bladder cancer and as a potential neoadjuvant for